EyePoint Pharmaceuticals, Inc. (EYPT)
- Previous Close
16.16 - Open
16.08 - Bid 16.69 x 100
- Ask 16.75 x 100
- Day's Range
15.65 - 16.76 - 52 Week Range
5.67 - 30.99 - Volume
1,140,190 - Avg. Volume
982,814 - Market Cap (intraday)
834.666M - Beta (5Y Monthly) 1.68
- PE Ratio (TTM)
-- - EPS (TTM)
-1.82 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
43.67
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
eyepointpharma.comRecent News: EYPT
Performance Overview: EYPT
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EYPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EYPT
Valuation Measures
Market Cap
834.67M
Enterprise Value
508.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.16
Price/Book (mrq)
3.13
Enterprise Value/Revenue
11.05
Enterprise Value/EBITDA
-7.37
Financial Highlights
Profitability and Income Statement
Profit Margin
-153.84%
Return on Assets (ttm)
-17.24%
Return on Equity (ttm)
-39.04%
Revenue (ttm)
46.02M
Net Income Avi to Common (ttm)
-70.8M
Diluted EPS (ttm)
-1.82
Balance Sheet and Cash Flow
Total Cash (mrq)
331.05M
Total Debt/Equity (mrq)
2.05%
Levered Free Cash Flow (ttm)
15.77M